Clinical Trial Update: 68Ga-DOTATATE PET/CT in Oncogenic Osteomalacia [EARLY_Phase 1]

View source ↗

Summary

Early-phase trial evaluating Ga-68 DOTATATE PET/CT to locate somatostatin receptor–expressing tumors causing oncogenic osteomalacia related to mesenchymal tumor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mesenchymal Tumor
• Tumor-induced Osteomalacia

Drugs mentioned

• 68Ga-DOTATATE (Gallium-68 DOTATATE)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Oncogenic Osteomalacia, Mesenchymal Tumor | EARLY_Phase 1 | Status: UNKNOWN